Surufatinib plus toripalimab and chemotherapy for second-line treatment of RAS/BRAF mutant (MT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC): A single-arm, phase II study (APHRODITE)

被引：0
|
作者：
Zhang, H. [1 ]
Liu, L. [1 ]
Zhu, X. [1 ]
Gao, Y. [1 ]
Tong, Z. [1 ]
Fu, Q. [1 ]
Bao, X. [1 ]
Dai, X. [1 ]
Zhao, P. [1 ]
Fang, W. [1 ]
Zheng, Y. [1 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Oncol Dept, Sch Med, Hangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
41P
引用
收藏
页码：S21 / S21
页数：1
相关论文
共 50 条
  • [1] Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial
    Ahn, Daniel H.
    Ridinger, Maya
    Cannon, Timothy L.
    Mendelsohn, Lawrence
    Starr, Jason S.
    Hubbard, Joleen M.
    Kasi, Anup
    Barzi, Afsaneh
    Samuelsz, Errin
    Karki, Anju
    Subramanian, Ramanand A.
    Yemane, Divora
    Kim, Roy
    Wu, Chu-Chiao
    Croucher, Peter J. P.
    Smeal, Tod
    Kabbinavar, Fairooz F.
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (07)
  • [2] Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
    Bocobo, Andrea Grace
    Wang, Renee
    Behr, Spencer
    Carnevale, Julia C.
    Cinar, Pelin
    Collisson, Eric Andrew
    Fong, Lawrence
    Keenan, Bridget P.
    Kidder, Wesley Allen
    Ko, Andrew H.
    Kolli, Kanti Pallav
    Kennedy, Megan
    Laffan, Angela
    Piawah, Sorbarikor
    Pollak, Marin
    Schwartz, Gabriel
    Whitman, Julia
    Zhang, Li
    Van Loon, Katherine
    Atreya, Chloe Evelyn
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] XELOX plus bev plus tislelizumab for first-line treatment of MSS/pMMR RAS-mutated mCRC: A single-arm, phase II study
    Ou, K.
    Ma, X.
    Cao, B.
    Yang, W.
    Yang, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S439 - S440
  • [4] Anlotinib combined with mXELIRI as second-line treatment in advanced colorectal cancer pretreated with bevacizumab plus standard chemotherapy: A single-arm, phase IB/II study
    Qu, Xin
    Chen, Xian
    Li, Yong
    Liu, Li-rong
    Qu, Yan-chun
    Hou, Fang-fang
    Li, Wen-zhu
    Liu, Yi-hong
    Zhu, Yan-juan
    Zhang, Haibo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [5] Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Interim analysis.
    Bocobo, Andrea Grace
    Wang, Renee
    Behr, Spencer
    Carnevale, Julia C.
    Cinar, Pelin
    Collisson, Eric Andrew
    Fong, Lawrence
    Kidder, Wesley Allen
    Ko, Andrew H.
    Kolli, Kanti Pallav
    Kennedy, Megan
    Laffan, Angela
    Lindsay, Sheila
    Nalla, Sneha
    Schwartz, Gabriel
    Whitman, Julia
    Zendejas, Patricia
    Zhang Li
    Van Loon, Katherine
    Atreya, Chloe Evelyn
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [6] Conatumumab (CON) plus FOLFIRI (F) or ganitumab (GAN) plus F for second-line treatment of mutant (MT) KRAS metastatic colorectal cancer (mCRC).
    Cohn, Allen Lee
    Tabernero, Josep
    Maurel, Juan
    Nowara, Elzbieta
    Dubey, Sarita
    Baker, Nigel
    Hei, Yong Jiang
    Galimi, Francesco
    Choo, SuPin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [7] A single-arm clinical study of continuous usage of bevacizumab as second-line chemotherapy for Chinese patients with metastatic colorectal cancer
    Wang, Guojun
    Ye, Yanwei
    Zhang, Xiefu
    Liu, Hongxiang
    Song, Junmin
    MEDICAL ONCOLOGY, 2015, 32 (05)
  • [8] A single-arm clinical study of continuous usage of bevacizumab as second-line chemotherapy for Chinese patients with metastatic colorectal cancer
    Guojun Wang
    Yanwei Ye
    Xiefu Zhang
    Hongxiang Liu
    Junmin Song
    Medical Oncology, 2015, 32
  • [9] Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study
    Xu, Xiaojing
    Ai, Luoyan
    Hu, Keshu
    Liang, Li
    Lv, Minzhi
    Wang, Yan
    Cui, Yuehong
    Li, Wei
    Li, Qian
    Yu, Shan
    Feng, Yi
    Liu, Qing
    Yang, Ying
    Zhang, Jiao
    Xu, Fei
    Yu, Yiyi
    Liu, Tianshu
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [10] Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial
    Fang, Xuefeng
    Zhu, Ning
    Zhong, Chenhan
    Wang, Liuhong
    Li, Jun
    Weng, Shanshan
    Hu, Hanguang
    Dong, Caixia
    Li, Dan
    Song, Yongmao
    Xu, Dong
    Wang, Jianwei
    Sun, Lifeng
    Wang, Jian
    Wang, Zhanhuai
    Cao, Hongfeng
    Liao, Xiujun
    Yu, Ningjuan
    Xiao, Qian
    Mi, Mi
    Zhang, Suzhan
    Ding, Kefeng
    Yuan, Ying
    ECLINICALMEDICINE, 2023, 62
12345